• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

byDaniel GoldshteinandSze Wah Samuel Chan
March 6, 2023
in Chronic Disease, Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%).

2. Grade 3 or higher adverse events were seen at similar rates across both groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with advanced melanoma (stage III or IV) are at high risk of relapse after undergoing surgical excision. Administering anti-PD-1 therapy has been shown to improve outcomes in the adjuvant setting but recent research has demonstrated benefit in the neoadjuvant setting due to the potential of activating antitumor T cells that are in the bulk of the tumour. This phase 2 study investigated this with the primary endpoint being event-free survival which was defined as postsurgical recurrence events, disease progression, and toxic effects. It was found that at 2 years, event-free survival was 72% in the neoadjuvant-adjuvant group vs 49% in the adjuvant-only group with overall event-free survival being significantly longer in the neoadjuvant-adjuvant group compared to the adjuvant-only group, p=0.004. This benefit of neoadjuvant therapy was seen across all subgroups. After neoadjuvant therapy, there was both an imaging-based response (6% complete, 41% partial) and a pathological response (21% complete). Grade 3 or higher adverse events were seen in 12% of the neoadjuvant–adjuvant group and 14% in the adjuvant-only group. The strength of this study was the length of follow-up. The limitations of this study included the small sample size and the composite endpoint. Overall, this study showed that neoadjuvant followed by adjuvant immunotherapy had longer event-free survival than adjuvant therapy alone in patients with stage III-IV melanoma and warrants further study to determine the more optimal curative strategy.

Click to read the study in NEJM

Relevant Reading: Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease.

In-Depth [randomized controlled trial]: This open-label phase 2 randomized control trial recruited patients with histologically confirmed melanoma stage IIIB to IIID or stage IV with resectable nodal metastases of 1.5cm or greater. Patients were randomly assigned to receive 3 doses of pembrolizumab as neoadjuvant therapy followed by 15 doses as adjuvant therapy (154 patients) vs receiving 18 doses as adjuvant therapy (159). The median follow-up time was 14.7 months. At 2 years, event-free survival was 72% (95%CI, 64-80) in the neoadjuvant-adjuvant group vs 49% (95%CI, 41-59) in the adjuvant-only group. Overall, event-free survival was found to be significantly longer in the neoadjuvant-adjuvant group compared to the adjuvant-only group, p=0.004. The benefit of neoadjuvant therapy was seen across all subgroups. Initial response to neoadjuvant therapy was investigated and it was found that 6% of patients had a complete imaging-based response, 41% had a partial imaging response, and 21% had a complete pathological response. Grade 3 or higher adverse events were seen in 12% of the neoadjuvant–adjuvant group and 14% in the adjuvant-only group. There were no deaths attributed to pembrolizumab in either group. Overall, this study showed that neoadjuvant-adjuvant therapy with pembrolizumab had longer event-free survival than the standard-care adjuvant pembrolizumab alone in patients with stage III-IV melanoma.

RELATED REPORTS

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: melanomaneoadjuvant immunotherapyPembrolizumab
Previous Post

Paid-sick-leave mandates contribute to increased cancer screening in the United States

Next Post

School nutritional quality programs associated with lower BMI in children

RelatedReports

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
StudyGraphics

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

March 15, 2023
#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
StudyGraphics

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

March 9, 2023
#VisualAbstract: Adjuvant pembrolizumab improves distant  metastasis-free survival in stage IIB-C melanoma
StudyGraphics

#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma

February 13, 2023
#VisualAbstract: Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest
StudyGraphics

#VisualAbstract: Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

December 22, 2022
Next Post
Eating in the absence of hunger linked to toddler obesity

School nutritional quality programs associated with lower BMI in children

Prevalence of hypertension among adolescents varies by race and BMI

Endovascular ultrasound renal denervation associated with lower ambulatory systolic blood pressure in patients with hypertension – The RADIANCE II randomized clinical trial

UTI associated with increased risk of preeclampsia

Ultrasound renal denervation associated with reduced blood pressure in the RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials – A pooled analysis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • United States patients receive subcutaneous fluids less frequently than intravenous fluids when compared to Canadian patients
  • Spirituality, among many other factors, may help promote healthy ageing
  • 2 Minute Medicine Rewind March 27, 2023
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options